OSTX — OS Therapies Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1795091 ·
Last close
$1.55
Market Cap
$71.50M
52W High
$2.25
52W Low
$1.40
ADV30
348,403
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,167,938 | -10,396,831 | 7,299,236 | 917,552 | 18,123,474 |
| Dec 2025 | 0 | — | -11,987,892 | -13,460,833 | 6,839,534 | 269,830 | 12,935,165 |
| Sep 2025 | 0 | — | -6,879,595 | -6,879,530 | 8,953,251 | 1,876,626 | 5,316,056 |
| Jun 2025 | 0 | — | -4,838,728 | -4,536,622 | 10,310,475 | 2,802,013 | 5,366,828 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,360,230
Investing CF
$-292,787
Financing CF
$13,599,562
CapEx
$-466,423
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.85
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,583,050
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,198,472
Pretax Income TTM
$-35,273,816
Interest Exp TTM
$75,344
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,705,701 | -28,753,844 | 6,839,534 | 12,935,165 | — | -14,238,576 |
| Dec 2024 | 0 | -6,813,846 | -8,882,938 | 5,538,797 | 8,805,335 | — | -7,282,295 |
| Dec 2023 | 0 | -4,342,645 | -7,791,582 | 798,082 | 24,814,297 | — | -3,006,967 |
| Dec 2022 | 0 | -4,446,299 | -6,254,685 | 509,105 | 18,066,333 | — | -3,792,580 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRO | Spero Therapeutics, Inc. | $70.76M | $1.22 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $70.59M | $1.14 | — |
| IBIO | iBio, Inc. | $70.54M | $1.42 | — |
| XBIT | XBiotech Inc. | $70.43M | $2.31 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $69.76M | $1.30 | — |
News headlines (Yahoo Finance, 1h cache)
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
2026-08-17 11:40 · Yahoo
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic
2026-08-13 12:45 · Yahoo
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
2026-07-08 13:00 · Yahoo
OS Therapies Third Quarter 2026 Corporate Outlook
2026-07-06 13:00 · Yahoo
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
2026-07-02 11:30 · Yahoo
OS Therapies Provides U.S. Regulatory Update
2026-06-30 11:40 · Yahoo
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
2026-06-26 11:40 · Yahoo
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
2026-06-08 10:00 · Yahoo
OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma
2026-06-02 10:25 · Yahoo
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
2026-06-02 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.